PD-L1 is a widely used biomarker for cancer patient selection for checkpoint inhibitors, a class of cancer drugs representing ...

Ultimately, the research showed that immune cells need physical as well as chemical cues to properly manage PD-1 activity, ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

Imdusiran data from IM-PROVE I and IM-PROVE II Phase 2a clinical trials to be presented at upcoming AASLD – The Liver Meeting 2024 Multiple-ascending doses of AB-101 in healthy subjects in the Phase ...

Keay Nakae, an analyst from Chardan Capital, maintained the Buy rating on Arbutus Biopharma (ABUS – Research Report). The associated ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer ...

Patients with advanced melanoma who have not previously received immune checkpoint inhibitors (ICI) often experience lasting clinical benefits ... The OS advantage was more notable in patients with ...

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today ...

Presentation Operator Good afternoon, everyone, and welcome to Gilead's Third Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with ...